Between those two events: 120 days. Before the first: 210 days. After the second, until the participant completes the trial: another 300 days or more. Add it up. Across two years of participation, formal reconsent occupies perhaps two conversations. The remaining 630 days -- nearly 22 months -- are the territory of ongoing consent. And for most of those months, at most sites, the consent process is functionally silent.

This is the gap that this lesson addresses. Not the dramatic moments when a protocol amendment or safety signal triggers formal reconsent -- you have already learned those procedures in the preceding lessons. This lesson is about what happens in the spaces between. The routine study visits where no one asks, "Are you still comfortable participating?" The months when new study information accumulates but never reaches the participant. The slow erosion of informed consent that occurs not through any single failure but through the quiet absence of ongoing communication.

I have seen this pattern at site after site across three decades. The team conducts an exemplary initial consent conversation. They execute reconsent flawlessly when triggered. And then they treat the intervals between those formal events as consent-free zones -- periods where the only obligation is to collect data and complete procedures. This is, in my view, the most widespread consent deficiency in clinical research. Not because it is dramatic, but precisely because it is invisible. No audit finding captures the conversation that never happened at Visit 6.

Between those two events: 120 days. Before the first: 210 days. After the second, until the participant completes the trial: another 300 days or more. Add it up. Across two years of participation, formal reconsent occupies perhaps two conversations. The remaining 630 days -- nearly 22 months -- are the territory of ongoing consent. And for most of those months, at most sites, the consent process is functionally silent.

This is the gap that this lesson addresses. Not the dramatic moments when a protocol amendment or safety signal triggers formal reconsent -- you have already learned those procedures in the preceding lessons. This lesson is about what happens in the spaces between. The routine study visits where no one asks, "Are you still comfortable participating?" The months when new study information accumulates but never reaches the participant. The slow erosion of informed consent that occurs not through any single failure but through the quiet absence of ongoing communication.

I have seen this pattern at site after site across three decades. The team conducts an exemplary initial consent conversation. They execute reconsent flawlessly when triggered. And then they treat the intervals between those formal events as consent-free zones -- periods where the only obligation is to collect data and complete procedures. This is, in my view, the most widespread consent deficiency in clinical research. Not because it is dramatic, but precisely because it is invisible. No audit finding captures the conversation that never happened at Visit 6.